Medicine and Dentistry
Epidermal Growth Factor Receptor
100%
Non-Small Cell Lung Cancer
100%
Neoplasm
50%
Gefitinib
50%
Erlotinib
50%
Exon
25%
Retrospective Study
12%
Malignant Neoplasm
12%
Adenocarcinoma
12%
Identified Patient
12%
Treatment Duration
12%
Anatomical Pathology
12%
Patient Referral
12%
Patient Characteristics
12%
Medical Record
12%
Nursing and Health Professions
Epidermal Growth Factor Receptor
100%
Gefitinib
50%
Neoplasm
50%
Erlotinib
50%
Clinical Practice
12%
Treatment Outcome
12%
Medical Record
12%
Malignant Neoplasm
12%
Patient Referral
12%
Female Patient
12%
Treatment Duration
12%
Adenocarcinoma
12%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Gefitinib
50%
Neoplasm
50%
Erlotinib
50%
Retrospective Study
12%
Malignant Neoplasm
12%
Adenocarcinoma
12%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
Gefitinib
50%
Erlotinib
50%
Exon
25%
Retrospective Study
12%
Medical Record
12%